ClinicalTrials.gg
CompletedNCT07137793PTX / BCUpdated Sep 30, 2026

Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

A Phase 2 interventional study of Pentoxifylline 400mg plus chemotherapy in Doxorubicin Induced Cardiotoxicity and Breast Cancer, sponsored by Tanta University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Tanta University · Phase 2, Interventional, and Prevention

How we know

Updated Sep 30, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Neoplasms by Tanta University — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Tanta University.

Enrollment
8th of 14
46 · median 48
Started
2025
with 2 others
Phase 2
4 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Breast Neoplasms by Tanta University, this one is the 8th largest by enrollment, is one of 3 that started in 2025, is one of 4 in phase 2, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 14 studies in Breast Neoplasms by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Neoplasms by Tanta University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the cardioprotective effect of pentoxifylline against doxorubicin-induced cardiotoxicity in breast cancer patients. The main questions it aims to answer are:

  1. What is the change in ejection fraction (primary outcome) in breast cancer patients receiving pentoxifylline compared to those who do not?
  2. What are the changes in serum levels of N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), and TNF-α (secondary outcomes) in breast cancer patients receiving pentoxifylline compared to those who do not? Researcher will compare breast cancer patients receiving standard chemotherapy alone (Group one: Positive control group; n=23) to breast cancer patients receiving standard chemotherapy plus pentoxifylline (Group two: pentoxifylline group; n=23) to see if pentoxifylline mitigates the cardiac side effects associated with doxorubicin treatment.

Participants will:

Be randomized to receive either a chemotherapeutic regimen alone or with pentoxifylline.

03

Conditions studied

  • Doxorubicin Induced Cardiotoxicity
  • Breast Cancer

Browse trials for

Keywords

  • pentoxyfillne
  • breast cancer
  • cardioprotective
  • Doxorubicin Induced Cardiotoxicity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old.
  • Chemo-naïve patients with confirmed diagnosis of breast cancer and with stage I-III breast cancer according to the American Joint Committee on Cancer (TNM staging system of breast cancer).
  • Patients intended to receive at least 4 cycles of doxorubicin or more.
  • Patients with performance status \<2 according to (ECOG) score.
  • Echocardiographic ≥55%.
  • Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 ×109/L, count ≥ 90 × 109/L and level ≥ 10 g/dl).
  • Patients with adequate liver function and adequate renal function.
  • Signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years old and >65 years old.
  • Women with history of breast cancer.
  • Formerly treated with DOX.
  • Patients with a known to any of the used drugs.
  • Treatment with blood thinners for 6 months prior to the screening.
  • Treatment with NSAIDS like ketorolac,ibuprofen.
  • Patients taking any other cardioprotective medications.
  • Pregnancy and breast feeding.
  • Alcohol abuse.
  • Creatine Clearance \< 50 mL/min.
  • History of heart failure or \<50%.
  • Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
46 participants (actual)

Study arms

  • No intervention
    Positive control group receiving standard chemotherapy for breast cancer .
  • Active comparator
    Pentoxifylline 400mg plus chemotherapy

    Drug: Pentoxifylline 400mg plus chemotherapy

Interventions

  • DrugPentoxifylline 400mg plus chemotherapy

    Drug page: PentoxifyllineStudies of PentoxifyllinePentoxifylline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    patient will receive standard chemotherapy for breast cancer plus pentoxifylline 400 mg orally 3 times per day with meals.

06

What researchers measure

Primary outcomes

  1. change in ejection fraction

    Time frame: 3 MONTHS

Secondary outcomes

  1. changes in serum levels of the measured biological markers

    Time frame: 3 MONTHS

07

Study locations

1 site
  • Damnhour Oncology Center
    Damanhūr, Egypt
08

References and documents

Publications

  • Matboli M, Habib EK, Hussein Mohamed R, Mahran NA, Seleem HS, Nosseir N, Hasanin AH. Pentoxifylline alleviated cardiac injury via modulating the cardiac expression of lncRNA-00654-miR-133a-SOX5 mRNA in the rat model of ischemia-reperfusion. Biomed Pharmacother. 2020 Apr;124:109842. doi: 10.1016/j.biopha.2020.109842. Epub 2020 Jan 20. PubMed 31972363 ↗
  • Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother. 1993;36(1):57-60. doi: 10.1007/BF01789132. PubMed 7678547 ↗
  • Fernandes JL, de Oliveira RTD, Mamoni RL, Coelho OR, Nicolau JC, Blotta MHSL, Serrano CV Jr. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study. Atherosclerosis. 2008 Jan;196(1):434-442. doi: 10.1016/j.atherosclerosis.2006.11.032. Epub 2006 Dec 28. PubMed 17196208 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Mar 2026, 6 months.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 6 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start May 2025 → Sep 2025, primary completion May 2026 → Mar 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 22, 2025
StartActual
Sep 1, 2025was May 2025
Primary completionActual
Mar 15, 2026was May 2026
CompletionActual
Sep 23, 2026was Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Start date
May 25, 2025→Sep 1, 2025
Sep 30, 2026
Primary completion
May 2026→Mar 15, 2026 (actual)
Sep 30, 2026
Study completion
Dec 2026→Sep 23, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Start date May 25, 2025→Sep 1, 2025
    Primary completion May 2026→Mar 15, 2026 (now actual)
    Study completion Dec 2026→Sep 23, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07137793
Lead sponsor
Tanta University
Responsible party
Sondos Mahmoud Elfeky (bachelor, Tanta University) — Principal investigator
First posted
Aug 22, 2025
Start date
Sep 1, 2025
Primary completion
Mar 15, 2026
Completion
Sep 23, 2026
Last update
Sep 30, 2026

Study contacts

Dalia Refaat Mohamed Elafify Dr
study chair · Tanta University
Eman Ibrahim Elberri Lecturer
study director · Tanta University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentoxifylline

Start the discussion